Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $81.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $75.00.

KROS has been the subject of several research reports. HC Wainwright lowered their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Truist Financial reduced their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a report on Monday. Jefferies Financial Group began coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $16.71 on Wednesday. The stock’s 50 day simple moving average is $54.10 and its 200 day simple moving average is $51.40. Keros Therapeutics has a one year low of $15.67 and a one year high of $73.00. The firm has a market cap of $676.87 million, a PE ratio of -3.21 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the firm earned ($1.33) EPS. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, equities analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KROS. KBC Group NV increased its stake in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP bought a new stake in shares of Keros Therapeutics in the third quarter worth about $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.